⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
globenewswire.com
REGN
AAFA Highlights New Resources for Nasal Polyps in Recognition of Global CRSwNP Awareness Day
globenewswire.com
AMGN
AZN
SNY
REGN
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
globenewswire.com
REGN
SNY
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
globenewswire.com
REGN
SNY
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
globenewswire.com
AZN
CRSP
NKTR
INCY
IPHA
ABBV
BIIB
ALKS
IMVT
CLRB
IMPP
REGN
THO
AUTL
KYMR
CBIO
GILD
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
globenewswire.com
REGN
THE SKIN OF COLOR SOCIETY (SOCS) SUCCESSFULLY PRESENTS LANDMARK SYMPOSIUM CHAMPIONING EVIDENCE-BASED DERMATOLOGY AND COLLABORATION
prnewswire.com
ABBV
JNJ
ARQT
BMY
LLY
INCY
SNY
REGN
PFE
UCB
BIIB
ORGN
TAK
ELMD
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook
globenewswire.com
JNJ
AMGN
GMAB
ABBV
AZN
PFE
BMY
REGN
XNCR
ZYME
Regeneron Announces Investor Conference Presentations
globenewswire.com
REGN
Foundation Fighting Blindness to Host United in Vision 2026 Conference in Partnership with Retina International World Congress
prnewswire.com
AMGN
ALKS
BLCO
AMR
MRK
REGN